These associations are consistent with the hypothesis that various oncogenic alterations involved in the activation of the MAPK pathway may lead to aberrations in tumor cell glycosylation and the enhanced expression of MGL ligands, influencing immunosuppression [47]. Here, CLEC10A is linked to neoplasm.